Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 5/20 | 0.52 |
| ▸ | ACHE | P22303 | 5/20 | 0.52 |
| ▸ | BACE1 | P56817 | 5/20 | 0.52 |
| ▸ | DRD2 | P14416 | 7/20 | 0.52 |
| ▸ | DRD4 | P21917 | 7/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1934958 | 0.93 | KMT2A (0.54) | KMT2AL3MBTL1BCHEACHEDRD2 | |
| SCHEMBL3635817 | 0.93 | KMT2A (0.56) | KMT2AL3MBTL1MCHR1BCHEDRD2 | |
| SCHEMBL2241423 | 0.89 | KMT2A (0.63) | KMT2AL3MBTL1MCHR1BCHEACHE | |
| SCHEMBL178929 | 0.89 | KMT2A (0.63) | KMT2AL3MBTL1MCHR1BCHEACHE | |
| SCHEMBL2241424 | 0.89 | KMT2A (0.63) | KMT2AL3MBTL1MCHR1BCHEACHE | |
| SCHEMBL1412221 | 0.85 | KMT2A (0.58) | KMT2AL3MBTL1MCHR1DRD2DRD4 | |
| SCHEMBL1412219 | 0.85 | KMT2A (0.58) | KMT2AL3MBTL1MCHR1DRD2DRD4 | |
| SCHEMBL915402 | 0.84 | KMT2A (0.65) | KMT2AL3MBTL1MCHR1DRD2DRD4 | |
| SCHEMBL555251 | 0.84 | KMT2A (0.62) | KMT2AL3MBTL1MCHR1DRD2DRD4 | |
| SCHEMBL1412348 | 0.83 | KMT2A (0.56) | KMT2AL3MBTL1MCHR1BACE1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291890-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-10-12 | — | — | US | disclosed |
| US-20170291890-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-10-12 | — | — | US | disclosed |
| EP-3194377-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016044666-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044666-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291890-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | HCCS, TP53, NME2 | KMT2A 2175/4885L3MBTL1 4229/4885MCHR1 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.